INVA Stock Overview
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Innoviva, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$15.17 |
52 Week High | US$16.87 |
52 Week Low | US$11.37 |
Beta | 0.57 |
1 Month Change | 0.53% |
3 Month Change | -8.17% |
1 Year Change | 27.80% |
3 Year Change | 30.89% |
5 Year Change | 8.75% |
Change since IPO | -16.23% |
Recent News & Updates
Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
Feb 05Is Innoviva (NASDAQ:INVA) A Risky Investment?
Nov 04Recent updates
Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly
Feb 05Is Innoviva (NASDAQ:INVA) A Risky Investment?
Nov 04Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly
Mar 02Innoviva Stock? Not Yet. Short Puts? Definitely.
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Sep 19Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?
Jun 16Continuing To Avoid Innoviva Inc.
Jun 07We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease
Mar 04Taking Innoviva Winnings Off The Table, Again
Feb 21Innoviva Inc.: Short Puts Are Compelling
Jan 15Is Innoviva (NASDAQ:INVA) A Risky Investment?
Oct 19Taking Profits In Innoviva Inc.
Oct 16Innoviva reports Q1 results
Apr 28These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Mar 30Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 04Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?
Jan 15These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely
Dec 25Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?
Dec 04Innoviva: Only For Short-Term Traders
Nov 04Innoviva reports Q3 results
Oct 28Shareholder Returns
INVA | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 4.8% | 0.9% | 1.2% |
1Y | 27.8% | 13.9% | 24.7% |
Return vs Industry: INVA exceeded the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: INVA exceeded the US Market which returned 24.7% over the past year.
Price Volatility
INVA volatility | |
---|---|
INVA Average Weekly Movement | 2.6% |
Pharmaceuticals Industry Average Movement | 9.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INVA has not had significant price volatility in the past 3 months.
Volatility Over Time: INVA's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 112 | Pavel Raifeld | www.inva.com |
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.
Innoviva, Inc. Fundamentals Summary
INVA fundamental statistics | |
---|---|
Market cap | US$959.16m |
Earnings (TTM) | US$179.72m |
Revenue (TTM) | US$310.46m |
5.3x
P/E Ratio3.1x
P/S RatioIs INVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INVA income statement (TTM) | |
---|---|
Revenue | US$310.46m |
Cost of Revenue | US$49.40m |
Gross Profit | US$261.07m |
Other Expenses | US$81.34m |
Earnings | US$179.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 2.84 |
Gross Margin | 84.09% |
Net Profit Margin | 57.89% |
Debt/Equity Ratio | 66.1% |
How did INVA perform over the long term?
See historical performance and comparison